Endurance RP Ltd banner

Endurance RP Ltd
HKEX:575

Watchlist Manager
Endurance RP Ltd Logo
Endurance RP Ltd
HKEX:575
Watchlist
Price: 0.8 HKD -4.76% Market Closed
Market Cap: HK$233.5m

Multiples-Based Value

The Multiples-Based Value of one Endurance RP Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 0.8 HKD, Endurance RP Ltd is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Endurance RP Ltd Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Endurance RP Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Endurance RP Ltd
HKEX:575
233.5m HKD 32.6 -7.3 -7.9 -7.9
US
Eli Lilly and Co
NYSE:LLY
847.5B USD 12.9 40.7 27.5 29.3
US
Johnson & Johnson
NYSE:JNJ
576.1B USD 6.2 21.7 15.1 18.6
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.3 11.5 12.9
US
Merck & Co Inc
NYSE:MRK
294.3B USD 4.6 16.3 10.1 12.3
CH
Novartis AG
SIX:NOVN
229.3B CHF 5.2 21.1 13 16.8
UK
AstraZeneca PLC
LSE:AZN
214.5B GBP 5.1 29.1 16.1 22.7
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.3 9.8 7.3 8.6
US
Pfizer Inc
NYSE:PFE
156.8B USD 2.5 19.9 7.7 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
119.6B USD 2.5 16.8 7.1 8.8
P/E Multiple
Earnings Growth PEG
HK
Endurance RP Ltd
HKEX:575
Average P/E: 21.6
Negative Multiple: -7.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.7
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
CH
Novartis AG
SIX:NOVN
21.1
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.1
26%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
1%
9.8
US
Pfizer Inc
NYSE:PFE
19.9
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
Endurance RP Ltd
HKEX:575
Average EV/EBITDA: 49.1
Negative Multiple: -7.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.5
22%
1.2
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
16.1
13%
1.2
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.3
1%
7.3
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
Endurance RP Ltd
HKEX:575
Average EV/EBIT: 108.1
Negative Multiple: -7.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.3
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2
CH
Novartis AG
SIX:NOVN
16.8
9%
1.9
UK
AstraZeneca PLC
LSE:AZN
22.7
21%
1.1
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.6
2%
4.3
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett